Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15015437 | 0.96 | TP53 (0.57) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL825658 | 0.87 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL15015485 | 0.84 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL2985063 | 0.84 | PDE4B (0.61) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL15015431 | 0.81 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL2999640 | 0.80 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL28414443 | 0.80 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL825643 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL7885470 | 0.79 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL825856 | 0.79 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466191-B2 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof | ZHANG HESHENG (CN) | 2013-06-18 | — | — | US | claimed |
| US-8466191-B2 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof | ZHANG HESHENG (CN) | 2013-06-18 | — | — | US | disclosed |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | PDE4A 2306/4885PDE4B 2498/4885PDE4C 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.